. 2023 Apr 7;12(8):1103. doi: 10.3390/cells12081103

Table 2.

List of allogenic cellular immunotherapies using the CRISPR-Cas9-based gene editing system.

Conditions Targeted	Targets Knocked out via CRISPR	Targets Knocked in (via Lentivirus or CRISPR)	Sponsor	Clinical Trial ID
Acute myeloid leukemia	CD33	None	Vor Biopharma	NCT05309733 [77]
Relapsed or refractory CD19⁺ leukemia and lymphoma	TRAC and β₂M	CD19 CAR (via lentivirus)	Chinese PLA General Hospital	NCT03166878 [68]
Relapsed or refractory leukemia and lymphoma	TRAC and β₂M	CD19⁺ CD20 CAR or CD19⁺ CD22 CAR (via lentivirus)	Chinese PLA General Hospital	NCT03398967 [69]
B cell acute lymphoblastic leukemia	TRAC and CD52	CD19 CAR (via lentivirus)	Great Ormond Street Hospital	NCT04557436 [70]
Elapsed/refractory B cell non-Hodgkin lymphoma	TRAC and PD1	CD19 CAR at TRAC loci (via CRISPR)	Caribou Biosciences, Inc.	NCT04637763 [50]
Relapsed or refractory T or B cell malignancies	TRAC, β₂M and CD70	CD70 CAR at TRAC loci (via CRISPR)	CRISPR Therapeutics AG	NCT04502446 [71]
Renal cell carcinoma	TRAC, β₂M and CD70	CD70 CAR at TRAC loci (via CRISPR)		NCT04438083 [72]
B cell malignancy	TRAC and β₂M	CD19 CAR at TRAC loci (via CRISPR)		NCT04035434 [73]
Relapsed or refractory multiple myeloma	TRAC and β₂M	BCMA CAR at TRAC loci (via CRISPR)		NCT04244656 [74]